Acceleron Pharma: Q2 Earnings Insights

Shares of Acceleron Pharma XLRN were flat in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share fell 208.82% over the past year to ($1.05), which missed the estimate of ($0.88).

Revenue of $27,940,000 declined by 29.71% year over year, which missed the estimate of $33,440,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Acceleron Pharma hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Aug 05, 2021

Time: 05:00 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.acceleronpharma.com%2F&eventid=3195810&sessionid=1&key=9F059079C9E9A39755885CEFC6A46039&regTag=&V2=false&sourcepage=register

Technicals

52-week high: $146.15

52-week low: $85.58

Price action over last quarter: Up 7.78%

Company Overview

Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therapies. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates. The company sometimes uses contract research organizations and research institutions outside the United States.